

The Manager
Company Announcements
Australian Stock Exchange
4th Floor
20 Bridge Street
SYDNEY NSW 2000

10 February 2006

Dear Sir

Resonance Health Gains TGA and CE Marking Full Quality Assurance System Approval Certificates

Key points:

- **Completed milestone in obtaining Certificates**
- **Reduction in costs combined with greater flexibility in software and process development**

Resonance Health Limited (ASX: RHT) announced today that its wholly-owned subsidiary, Resonance Health Analysis Services Pty Ltd, has been issued Therapeutic Goods Administration (TGA) of Australia and European CE Marking Full Quality Assurance System Approval Certificates.


These new certifications will replace the existing requirements to obtain TGA and CE Mark clearance for each version of the FerriScan[®] analysis software and each individual batch of FerriScan Phantom Packs (used for the verification of Magnetic Resonance Imaging scanners for FerriScan analysis). The benefits include both a reduction in resources (as a result of not having to apply for multiple assessments) and also a greater flexibility in software and process development.

FerriScan has previously been listed on the Australian Register of Therapeutic Goods (ARTG) by the TGA, has been granted the European CE Mark, and has been granted marketing clearance in the US by the Food and Drug Administration (FDA).

Further Information:

About Resonance Health Ltd

Resonance Health (ASX: RHT) is an Australian Healthcare company specialising in the development and commercialisation of magnetic resonance imaging (MRI)-related technology for the quantitative measurement of iron levels in the human body. Our mission is to develop and market our technologies to assist in the diagnosis and management of patients suffering from iron-related conditions, whilst delivering significant added value for our MRI customers who deliver our service through their networks.



Resonance Health

In 2005, RHT began the global commercial launch of FerriScan, its world-leading non-invasive tool for measuring liver iron levels.

The FerriScan service involves an MRI scan followed by off-site processing of the images by RHT using its patented methodology to generate the liver iron concentration result. MR data is transmitted electronically via a secure data process to the RHT analysis centre from anywhere in the world. The test requires no new equipment purchase at the MRI centre level. FerriScan provides a significant improvement over current blood markers and invasive surgical procedures. This improvement leads to increased clinical efficiency and accuracy in diagnosis, in addition to allowing optimisation of treatment programs for iron-related disorders such as hereditary haemochromatosis and thalassemia. FerriScan is now positioned to become a routine part of the clinical diagnosis and management of iron loading disorders as well as playing a major role in the testing and monitoring of drugs used to treat these conditions.

FerriScan has received regulatory clearance to be marketed in the US, Australia, UK and Europe. Further information about Resonance Health and FerriScan can be obtained from the following websites: www.resonancehealth.com and www.ferriscan.com.

For further information on the Therapeutic Goods Administration visit www.tga.health.gov.au.

Media and Investor Relations	Resonance Health
Rebecca Piercy Buchan Consulting T - +61 3 9866 4722 M - +61 422 916 422 Email: rpiercy@bcg.com.au	Dr James Williams Managing Director Resonance Health Limited T - +61 8 9286 5300 M - +61 409 050 519 Email: jamesw@ferriscan.com